Abstract
Background: Circulating cell-free miRNAs hold great promise as a new class of biomarkers due to their high stability in body fluids and association with disease stages. However, even using sensitive and specific methods, technical challenges are associated with miRNA analysis in body fluids. A major source of variation in plasma and serum is the potential cell-derived miRNA contamination from hemolysis.
Objectives: The study aimed to evaluate the effect of the delayed whole blood processing time on the concentrations of miR-1 and -423-5p.
Methods: Ten blood samples were incubated for 0, 3 and 24 hours at room temperature prior to processing into plasma. For each time point, hemolysis was assessed in plasma by UV spectrophotometry at 414nm wavelength (λ414). Circulating levels of miR-1 and -423-5p were measured by RT-qPCR; miR-23a and -451 were also analyzed as controls.
Results: A significant hemolysis was observed only after 24h (λ414 0.3 ± 0.02, p < 0.001). However, only small changes in miR-1 and -423-5p levels were observed up to 24h of storage at room temperature (Ct 31.5 ± 0.5 to 31.8 ± 0.6for miR-1, p = 0.989; and 29.01 ± 0.3 to 29.04 ± 0.3, p = 0.614 for - 423-5p). No correlation was observed between hemolysis and the levels of miR-1 and -423-5p.
Conclusion: Our data indicate that the storage of whole blood samples at room temperature for up to 24h prior to their processing into plasma does not appear to have a significant impact on miR-1 and - 423-5p concentrations.
Keywords: Biomarker, heart failure, hemolysis, microRNA, plasma, stability.
Graphical Abstract
MicroRNA
Title:Impact of Delayed Whole Blood Processing Time on Plasma Levels of miR- 1 and miR-423-5p up to 24 Hours
Volume: 7 Issue: 2
Author(s): Danielle Pazzotti Borges, Edecio Cunha-Neto, Edimar A. Bocchi and Vagner Oliveira Carvalho Rigaud*
Affiliation:
- Heart Failure Unit, Heart Institute (InCor) School of Medicine, University of Sao Paulo, Sao Paulo,Brazil
Keywords: Biomarker, heart failure, hemolysis, microRNA, plasma, stability.
Abstract: Background: Circulating cell-free miRNAs hold great promise as a new class of biomarkers due to their high stability in body fluids and association with disease stages. However, even using sensitive and specific methods, technical challenges are associated with miRNA analysis in body fluids. A major source of variation in plasma and serum is the potential cell-derived miRNA contamination from hemolysis.
Objectives: The study aimed to evaluate the effect of the delayed whole blood processing time on the concentrations of miR-1 and -423-5p.
Methods: Ten blood samples were incubated for 0, 3 and 24 hours at room temperature prior to processing into plasma. For each time point, hemolysis was assessed in plasma by UV spectrophotometry at 414nm wavelength (λ414). Circulating levels of miR-1 and -423-5p were measured by RT-qPCR; miR-23a and -451 were also analyzed as controls.
Results: A significant hemolysis was observed only after 24h (λ414 0.3 ± 0.02, p < 0.001). However, only small changes in miR-1 and -423-5p levels were observed up to 24h of storage at room temperature (Ct 31.5 ± 0.5 to 31.8 ± 0.6for miR-1, p = 0.989; and 29.01 ± 0.3 to 29.04 ± 0.3, p = 0.614 for - 423-5p). No correlation was observed between hemolysis and the levels of miR-1 and -423-5p.
Conclusion: Our data indicate that the storage of whole blood samples at room temperature for up to 24h prior to their processing into plasma does not appear to have a significant impact on miR-1 and - 423-5p concentrations.
Export Options
About this article
Cite this article as:
Borges Pazzotti Danielle , Cunha-Neto Edecio , Bocchi A. Edimar and Rigaud Oliveira Carvalho Vagner *, Impact of Delayed Whole Blood Processing Time on Plasma Levels of miR- 1 and miR-423-5p up to 24 Hours, MicroRNA 2018; 7 (2) . https://dx.doi.org/10.2174/2211536607666180322093119
DOI https://dx.doi.org/10.2174/2211536607666180322093119 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Coronary Microcirculation in Heart Failure with Preserved Systolic Function
Current Pharmaceutical Design The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease
Current Vascular Pharmacology Application of Erythropoietin in Chronic Heart Failure Treatment
Mini-Reviews in Medicinal Chemistry Treatment of Tachycardia in Hypertension: Where Do We Stand Now?
Current Hypertension Reviews Targeting Inflammation in Primary Cardiovascular Prevention
Current Pharmaceutical Design Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Analytical Techniques for the Estimation of Perindopril Erbumine: A Review
Current Pharmaceutical Analysis The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets Current Management of Vascular Tumors in the Neonate
Current Pediatric Reviews Targeting Eosinophils in Asthma
Current Molecular Medicine Development of Nitrendipine Nanoliposome for Transdermal Drug Delivery: Preparation, Characterization and Permeation Studies
Drug Delivery Letters C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Platelet Ca2+ATPases: Identification and Regulation in Hypertension
Current Hypertension Reviews Bilosomes: A Novel Approach to Meet the Challenges in Oral Immunization
Recent Patents on Drug Delivery & Formulation Recent Advances in Molecular Modeling and Medicinal Chemistry Aspects of Phospho-Glycoprotein&#
Current Drug Metabolism Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry Chemistry, Physiology, and Pharmacology of β-Adrenergic Mechanisms in the Heart. Why are β-Blocker Antiarrhythmics Superior?
Current Pharmaceutical Design Editorial (Hot Topic: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage)
Current Pharmaceutical Design